

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Comparison of Ventolin nebulizer with supportive treatment in Transient tachypnea of the newborns (TTN) admitted to the neonatal intensive care unit (NICU) of Imam Khomeini and Bouali Sari hospitals of Sari

Protocol summary

Study aim

The aim of this study is to compare Ventolin nebulizer with supportive treatment in transient respiratory rate of newborns and different intensities of their respiratory distress

Design

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 0 on 60 patients randomized by Stratified Permuted Block Randomization method with blocks of 4

Settings and conduct

This double-blind randomized clinical trial is conducted in infants with TTN hospitalized in the NICU of Imam and Boali Hospitals of Sari. Patients are randomly selected by the Stratified Permuted Block Randomization method with blocks of 4 and divided into two intervention and control groups in parallel. Patients and nurses will not know about the allocation of patients to study groups.

Participants/Inclusion and exclusion criteria

Neonates with gestational age >34 weeks who meet the criteria for TTN are included in the study. In case of meconium aspiration, pneumonia, complex Coronary heart disease (CHD), Tachycardia above 180, Silverman Anderson score less than 46, Ventilator therapy since birth, diagnosis of RDS during hospitalization and administration of surfactant, they are excluded.

Intervention groups

In the intervention group, 0.1 mL of salbutamol (Ventolin, salbutamol sulfate 5 mg/mL) is nebulized in 3 mL of 0.9% normal saline. The standard dose of salbutamol is 0.15 mg/kg/dose. It will be nebulized every day with a jet-type nebulizer with a continuous oxygen flow of 5 liters per minute during a 10-minute period and every 6 hours for a day. In the control group, they will receive 2 mL of 0.9% saline as a nebulizer.

Main outcome variables

Primary outcomes: duration of initial CPAP and oxygen

therapy; O2 and CO2 after nebulizer; Hospitalization days; Time to start feeding based on Silverman Anderson score I<4; stabilization of heart rate, breathing and Spo2; Absence of abdominal distension

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20091201002801N6**

Registration date: **2023-07-23, 1402/05/01**

Registration timing: **registered_while_recruiting**

Last update: **2023-07-23, 1402/05/01**

Update count: **0**

Registration date

2023-07-23, 1402/05/01

Registrant information

Name

Roya Farhadi

Name of organization / entity

Mazandaran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 11 3334 3018

Email address

rfarhadi@mazums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-07-01, 1402/04/10

Expected recruitment end date

2024-03-19, 1402/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of Ventolin nebulizer with supportive treatment in Transient tachypnea of the newborns (TTN) admitted to the neonatal intensive care unit (NICU) of Imam Khomeini and Bouali Sari hospitals of Sari

Public title

Comparison of Ventolin nebulizer with supportive treatment in Transient tachypnea of the newborns (TTN) admitted to the neonatal intensive care unit (NICU) of Imam Khomeini and Bouali Sari hospitals of Sari

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Neonates with gestational age more than 34 weeks
Tachypnea with or without cyanosis Respiratory distress
Chest X-ray findings in favor of TTN

Exclusion criteria:

Meconium aspiration Other diseases in the radiography such as pneumonia and... Complex Coronary heart disease (CHD) Tachycardia above 180 Silverman Anderson score less than 46 Ventilator therapy since birth Diagnosis of RDS during hospitalization Administration of surfactant with diagnosis of RDS

Age

From **1 year** old to **30 days** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Allocation of patients into two treatment groups will be by Stratified Permuted Block Randomization method with blocks of 4. First the patients are divided into two groups based on the severity of TTN, then in each group, using Block Randomization, the patients will receive one of the interventions. To generate random allocation, the sealed envelope site was used, which created the a random table with the code 105487821465911 for us, which shows how patients enter the two intervention groups.

Blinding (investigator's opinion)

Double blinded

Blinding description

The nurse and the study participants do not know who is in which group. Placebo and drug have the same color and shape in appearance and are coded by the

researcher and each patient will be given a drug code. Then the mediation is given to the nurse and nebulized.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Mazandaran University of Medical Sciences

Street address

Vice chancellor for Research, Moallem square, Sari, Iran

City

Sari

Province

Mazandaran

Postal code

4712855689

Approval date

2023-07-12, 1402/04/21

Ethics committee reference number

IR.MAZUMS.REC.1402.166

Health conditions studied**1****Description of health condition studied**

Transient tachypnea of newborn

ICD-10 code

P22.1

ICD-10 code description

Transient tachypnea of newborn

Primary outcomes**1****Description**

Primary CPAP (continuous positive airway pressure) duration

Timepoint

Time interval from start to end of CPAP

Method of measurement

Minute and hour

2**Description**

Oxygen therapy duration

Timepoint

Time interval from start to end of Oxygen therapy

Method of measurement

Minute and hour

3

Description

Hospitalization length

Timepoint

Time from hospitalization to discharge

Method of measurement

Day

4

Description

Time to start feeding based on Silverman Anderson score less than 4

Timepoint

Time to start feeding in day

Method of measurement

Calendar

5

Description

Stabilization of respiratory rate and heart rate

Timepoint

Calculate the stabilization time of respiratory rate and heart rate

Method of measurement

Hour

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: In the intervention group, 0.1 mL of salbutamol (Ventolin, salbutamol sulfate 5 mg/mL) is nebulized in 3 mL of 0.9% normal saline. The standard dose of salbutamol is 0.15 mg/kg/dose. It will be nebulized every day with a jet-type nebulizer with a continuous oxygen flow of 5 liters per minute during a 10-minute period and every 6 hours for a day

Category

Treatment - Drugs

2

Description

Control group: In the control group, they will receive 2 mL of 0.9% saline as a nebulizer.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Bouali Sina Hospital of Sari

Full name of responsible person

Roya Farhadi

Street address

Bouali Hospital, Pasdaran Boulevard

City

Sari

Province

Mazandaran

Postal code

4815838477

Phone

+98 11 3334 3018

Fax

+98 11 3334 4506

Email

rfarhadi@mazums.ac.ir

2

Recruitment center

Name of recruitment center

Imam Khomeini Hospital, Sari

Full name of responsible person

Roya Farhadi

Street address

Imam Hospital, Amir Mazandarani Boulevard, Sari

City

Sari

Province

Mazandaran

Postal code

4815838477

Phone

+98 11 3334 3010

Email

rfarhadi@mazums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research, Mazandaran University of Medical Sciences

Full name of responsible person

Pedram Ebrahimnejad

Street address

Vice chancellor for Research, Moallem square, Sari, Iran

City

Sari

Province

Mazandaran

Postal code

4712855689

Phone

+98 11 3448 4800

Email
pebrahimnejad@mazums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Vice chancellor for research, Mazandaran University of Medical Sciences

Proportion provided by this source
100

Public or private sector
Public

Domestic or foreign origin
Domestic

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences

Full name of responsible person
Maedeh Gouran

Position
Resident of Pediatrics

Latest degree
Medical doctor

Other areas of specialty/work
Pediatrics

Street address
ساری بلوار پاسداران بیمارستان بوعلی، مرکز تحقیقات عفونی اطفال

City
ساری

Province
Mazandaran

Postal code
4815838477

Phone
+98 11 3334 2334

Fax

Email
maedeh.gouran@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences

Full name of responsible person
Roya Farhadi

Position
Associate Professor

Latest degree
Subspecialist

Other areas of specialty/work
Pediatrics

Street address
Booali hospital. Pasdaran Blvd

City
Sari

Province
Mazandaran

Postal code
4815838477

Phone
+98 11 3334 3018

Fax
+98 11 3334 4506

Email
rfarhadi@mazums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Mazandaran University of Medical Sciences

Full name of responsible person
Roya Farhadi

Position
Associate Professor

Latest degree
Subspecialist

Other areas of specialty/work
Pediatrics

Street address
Booali hospital. Pasdaran Blvd

City
Sari

Province
Mazandaran

Postal code
4815838477

Phone
+98 11 3334 3018

Fax
+98 11 3334 4506

Email
rfarhadi@mazums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available

Study Protocol
No - There is not a plan to make this available

Statistical Analysis Plan
No - There is not a plan to make this available

Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report
Yes - There is a plan to make this available

Analytic Code
No - There is not a plan to make this available

Data Dictionary
No - There is not a plan to make this available

Title and more details about the data/document

Contact Dr. Roya Farhadi

When the data will become available and for how long

Informations will send within few days after the email.

To whom data/document is available

People working in academic institutions

Under which criteria data/document could be used

Contact Dr. Roya Farhadi

From where data/document is obtainable

Email

What processes are involved for a request to access data/document

Informations will send within few days after the email.

Comments